TP53 and plasma cell myeloma: In contrast, two investigations found the presence of CH involving DNMT3A, TET2, ASXL1, TP53, and PPM1D among others to be associated with inferior outcomes in patients undergoing autologous hematopoietic transplantation for multiple myeloma [22] and lymphoma [23].